Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Shares Outstanding data on record, last reported at $55.1 million in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 4.12% year-over-year to $55.1 million; the TTM value through Sep 2025 reached $55.1 million, up 4.12%, while the annual FY2024 figure was $54.0 million, 17.67% up from the prior year.
  • Shares Outstanding reached $55.1 million in Q3 2025 per STOK's latest filing, up from $54.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $55.1 million in Q3 2025 and bottomed at $39.0 million in Q1 2022.
  • Average Shares Outstanding over 4 years is $47.1 million, with a median of $45.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: grew 19.52% in 2024, then grew 4.12% in 2025.
  • A 4-year view of Shares Outstanding shows it stood at $39.4 million in 2022, then rose by 16.43% to $45.9 million in 2023, then grew by 17.67% to $54.0 million in 2024, then increased by 2.01% to $55.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $55.1 million in Q3 2025, $54.7 million in Q2 2025, and $54.6 million in Q1 2025.